Eli Lilly and Company — Onswik (insulin efsitora alfa-gobe) $LLY

for adults with type 2 diabetes mellitus (glycemic control, once-weekly basal insulin)

BLA

FDA approved Onswik (insulin efsitora alfa-gobe) on September 24, 2026 as a once-weekly basal insulin for adults with type 2 diabetes, the second in the US after Novo Nordisk's Awiqli (insulin icodec), approved March 27, 2026. Efsitora reduces basal injections from approximately 365 to 52 per year vs a once-daily basal insulin. Approval based on the four Phase 3 QWINT trials. Fourth global approval in type 2 diabetes following EU, Mexico, and Japan.